Lanean...
Clinical potential of brodalumab in the management of psoriasis: the evidence to date
Brodalumab is an anti-IL-17 receptor monoclonal antibody currently in development for the treatment of moderate-to-severe plaque psoriasis. With many systemic psoriasis therapies to choose from, and several newer agents in development, physicians need up to date evidence for the use of these drugs....
Gorde:
| Argitaratua izan da: | Psoriasis (Auckl) |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove Medical Press
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5683110/ https://ncbi.nlm.nih.gov/pubmed/29387580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PTT.S49996 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|